Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

There are lots of reasons why physicians and patients (and payers) might prefer one drug over another for the treatment of a given disease. Efficacy and safety are paramount, of course, but there are ...

When patients consider joining clinical trials, we often assume their decisions are logical—balancing risks and benefits. In reality, emotions like fear, hope, trust, and personal history play a far ...